Company Overview and News
OCK Group Bhd (Oct 11, 56.5 sen) Maintain outperform with an unchanged target price (TP) of 75 sen: OCK Group Bhd ventured into Vietnam’s telecommunications tower business in January 2017 through 60%-owned Southeast Asia Telecommunications Holdings Pte Ltd (SEATH). SEATH is the largest independent base transceiver station owner in Vietnam, with 1,998 telecommunications towers (as of end-calendar year 2017 and accounted for about 19% of independent tower market share) geographically dispersed throughout Vietnam.
Crucial disagreements and the specter of a legal row emerged Thursday during the initial public consultation on the country’s first-ever common cell tower policy, a key initiative of the administration to support a new major telco player once it is selected before the end of 2018.
GLO AMT GTMEY GTMEF GLOPP 0172 GLOPA
The country’s largest lender BDO Unibank has opened a P2-billion credit facility for the real estate business of young tycoon Michael Cosiquien, cofounder of Megawide Construction Corp., who is now building his own business empire.
BDOUF BDO MWP BDOUY MWIDE 0172
2018-03-29 thestar.com.my - 1
OCK managing director Sam Ooi Chin Khoon(pic) said in the same statement: “The management of OCK is very excited with our potential new venture and collaboration with ISOC into the Philippines as there are lots of opportunities in this country, with a population of over 100 million and the recent possible new entrant into the telecommunications industry.
MWP MWIDE AGF 0172
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...